Conditions: Zollinger-Ellison Syndrome
Keywords: YF476 netazepide gastric carcinoids Zollinger-Ellison syndrome
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 3
Healthy volunteers: no

Brief summary:
This study will evaluate whether treatment with YF476 is safe and effective in reducing the size of type II gastric carcinoid tumours, or limiting the abnormal growth of gastric ECL cells, in patients with Zollinger-Ellison syndrome.

Detailed description:

Arms:
arm 1: The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.

Interventions: intervention 1: YF476
Intervention descriptions: intervention 1: Gastrin receptor antagonist

Protocol document: